LABOMAR

What LABOMAR does

Labomar S.p.A. is an Italian contract development and manufacturing organization (CDMO) founded in 1998 by third-generation pharmacist Walter Bertin, headquartered in Istrana (Treviso), Italy. The company develops and manufactures dietary supplements, medical devices, cosmetics, and foods for special medical purposes on a B2B basis for international pharmaceutical, nutraceutical, and cosmetic brands — serving over 100 enterprise customers across Europe, North America, and select Asian and Middle Eastern markets. Its technology stack centers on patented and patent-pending proprietary formulations including Mucowall and the forthcoming CLT 25/ChoLnexT 25 botanical extract for cholesterol management, supported by ISO-certified cleanroom manufacturing (notably via the Welcare subsidiary in Orvieto), 7,000 m² of logistics capacity at the L6 hub, and EU regulatory expertise across multiple health-product categories. The company also runs CE-certified medical device production through Welcare, probiotic and supplement manufacturing through the recently acquired Finnish subsidiary Pharmia, and functional cosmetics production through Spain's Laboratorios Entema.

The business model is quote-based contract manufacturing with no public pricing, targeting large enterprise clients primarily through direct field sales. Revenue grew from approximately €57 million in 2019 to €135 million in 2025 (+34% YoY), with EBITDA of €27 million and 60% of revenue from overseas markets. The group structure includes wholly-owned subsidiaries Welcare Industries (medical devices, Italy), Labiotre Srl, Labomar Canada, ImportFab, and Labofit Srl, plus majority-owned Laboratorios Entema (Spain) and Pharmia Holding Oy (Finland). Following a 2023 take-private backed by Charterhouse Capital Partners and subsequent capital injections from Tikehau Capital (€120M senior bond, 2025) and AltamarCAM Partners (2026), Labomar is executing a 2025-2028 Industrial Plan explicitly targeting to double group size, funded through both organic capacity expansion and continued M&A in Europe.

Name

LABOMAR

Legal name

Labomar S.p.A. a socio unico

Website

https://labomar.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

51–100 employees

Short description

Labomar is an Italian CDMO founded in 1998 that develops and manufactures dietary supplements, medical devices, cosmetics, and foods for special medical purposes for over 100 international pharmaceutical, nutraceutical, and healthcare brand clients across Europe and North America.

Ownership category

akta.pro rank

Product category

Contract Development and Manufacturing (CDMO) for nutraceuticals, medical devices, and cosmetics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medical Equipment and Supplies Manufacturing (3391)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• Contract development manufacturing
• Dietary supplements CDMO
• Nutraceutical manufacturing services
• Medical device manufacturing
• Functional cosmetics production

Headquarters

HQ city

Istrana

HQ country

Italy

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing (CDMO): Labomar generates revenue through contract development and manufacturing services for dietary supplements, medical devices, cosmetics, and foods for special medical purposes. The company operates as a CDMO serving international brands.
2. Product Development Services: Research and development services for bespoke customized products, offering personalized advice on Italian and European industry directives and regulations

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Labomar is a one-stop-shop Contract Development and Manufacturing Organization (CDMO) that develops and manufactures dietary supplements, medical devices, pharmaceuticals, foods for special medical uses, and cosmetics on behalf of pharmaceutical, nutraceutical, and cosmetic brand owners. The company combines proprietary patented technologies (Mucowall, CLT 25/ChoLnexT 25), regulatory expertise for Italian and European markets, and multiple ISO-certified manufacturing facilities across Italy, Spain, Finland, and Canada to deliver customized products at industrial scale.

Product overview

Labomar is a nutraceutical CDMO (Contract Development and Manufacturing Organization) offering one-stop-shop development and manufacturing services. The portfolio includes: food supplements and dietary supplements (such as CLT 25 – ChoLnexT™ 25 for cholesterol management, probiotic formulations); medical devices and biocides (via Welcare subsidiary); functional cosmetics; foods for special medical uses; and CE-certified medical devices. Acquired companies include Pharmia (Finnish probiotics and medical devices), Welcare (medical devices and biocides), and Laboratorios Entema (Spanish functional cosmetics and medical devices). The company operates pharmaceutical form production capabilities and provides regulatory guidance for Italian and European markets.

Differentiator

Problem solved

Functional benefit

Brands

• Welcare: Leading company in the production of medical devices, biocides and customised solutions for patients and caregivers. Became a Benefit Corporation in 2024.
• Pharmia
• Laboratorios Entema
• BeCircular

Products and services

• One-Stop-Shop CDMO Services Contract development and manufacturing services covering the most sought-after pharmaceutical forms on the market, including dietary supplements, medical devices, pharmaceuticals, foods for special medical uses, and cosmetics, with personalised advice on Italian and European industry directives and regulations. Targeted at pharmaceutical, nutraceutical, medical device, and cosmetic brand owners.
• Food Supplements / Dietary Supplements Contract-manufactured dietary supplements for health applications including non-celiac gluten sensitivity (NCGS) support, cardiovascular health, and probiotic products, supplied to pharmaceutical and nutraceutical brand owners.
• CLT 25 - ChoLnexT 25 Patented-pending botanical formulation for cholesterol management and lipid metabolism support, free of red yeast rice and berberine, with clinical evidence; developed and supplied to nutraceutical and pharmaceutical brand customers.
• Mucowall Patent-protected proprietary technology used in Labomar's product development for nutraceutical applications.
• Welcare Medical Devices and Biocides Medical devices, biocides, and customised solutions for patients and caregivers, with specialisation in treatment of complex skin conditions and prevention of healthcare-associated infections; produced by the Welcare Industries subsidiary of Labomar Group.
• CE-Certified Medical Devices CE-certified medical devices produced through Labomar's contract development and manufacturing model, including probiotic-based devices, for healthcare and pharmaceutical brand customers.
• Functional Cosmetics Cosmetics and cosmeceuticals developed and manufactured for retail channels under the CDMO model, including functional and innovative formulations; capacity strengthened by the Laboratorios Entema acquisition.
• Foods for Special Medical Uses (FSMP) Foods designed for special medical purposes, manufactured under Labomar's contract development and manufacturing organization model for pharmaceutical and nutritional brand customers.
• Pharmia Probiotics and Food Supplements Contract-manufactured food supplements, probiotics, and CE-certified medical devices produced by Pharmia Holding Oy in Tuusula, Finland, serving Northern European nutraceutical brand customers.

Quantifiable outcome

• 34% revenue growth in 2025 to €135 million
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered major, minor and core.

• Pharmia Holding OymajorStrategic or Co-development Partner · 1 October 2025Finnish contract manufacturer of food supplements, probiotics and CE-certified medical devices. Acquired October 2025 from CapMan Buyout. Strengthens presence in Nordic region.
• Laboratorios EntemamajorStrategic or Co-development Partner · 1 August 2024Acquired majority stake in August 2024. Spanish CDMO specializing in functional cosmetics, medical devices, and hygiene products. Strengthens Labomar's position in Spain and functional cosmetics sector.
• NoventureminorStrategic or Co-development Partner · 1 January 2022Partnership strengthened in July 2022 for product development collaboration.
• BayercoreStrategic or Co-development Partner · 1 January 2021Long-standing manufacturing partnership for dietary supplements including Aspi Gola Natura and Supradyn Difese 50+. Awarded 'Best External Partner 2021'. New collaboration announced in May 2021.
• AlfasigmamajorStrategic or Co-development Partner · 1 January 2021Pharmaceutical group collaboration started in May 2021 for development projects in the nutraceutical sector.
• ZEROminorStrategic or Co-development Partner · 1 January 2021Labomar subsidiary that signed distribution agreement in Saudi Arabia in May 2022.
• Labiotre SrlminorStrategic or Co-development Partner · 1 January 2021Italian company in which Labomar built stake from 17.6% to 48.8% in 2021, then to 100% control in November 2021.
• Gruppo SesaminorStrategic or Co-development Partner · 1 January 2021Industrial partnership resulting in LaboVar in September 2021.
• Welcare IndustriescoreStrategic or Co-development PartnerSubsidiary specializing in medical devices, biocides and customised solutions for patients and caregivers. Became Società Benefit in 2024. Inaugurated new €4.5M manufacturing facility in Orvieto in September 2025.
• ICE (Italian Trade Agency)minorChannel Partner/ Reseller/ DistributorCollaboration for international trade show presence including HNCEXPO Shanghai 2025 (Hall 3 Padiglione G20-7).

Scale indicators12 records

Recent moves11 records

Expansion highlights7 records

Direct peers

• Procemsa (Probiotical / Alfasigma CDMO ecosystem): Italian probiotic and nutraceutical CDMO serving international brand customers across food supplements and probiotic medical devices. Directly overlaps with Labomar's probiotic and dietary-supply manufacturing book following the Pharmia (FI) acquisition.
• Biofarma Group: Italian CDMO specializing in nutraceuticals, food supplements, medical devices and cosmetics — direct head-to-head overlap with Labomar across dosage forms and customer base, particularly for Italian and Southern European brand customers.
• Sterling Pharma Solutions: UK-headquartered CDMO providing API and finished dosage development and manufacturing services for pharma and consumer health. Comparable mid-sized, privately owned CDMO with active M&A history and customer overlap with brand-led consumer-health customers.
• Hovione: Portuguese CDMO with integrated drug substance and drug product services and growing consumer-health exposure. Comparable integrated CDMO model combining chemical/process R&D with finished dosage manufacturing for international brand customers.
• Aenova Group: One of Europe's largest CDMOs, headquartered in Germany, with capabilities across softgels, capsules, tablets, sterile liquids and semi-solids for pharma, nutraceutical and consumer health. Most directly comparable European peer to Labomar across CDMO scale, customer overlap (multinational pharma/consumer health), and dosage-form breadth.
• Recipharm: Swedish-headquartered CDMO owned by Advent International, offering development and manufacturing of pharmaceuticals in multiple dosage forms with growing exposure to consumer health. Comparable pan-European CDMO profile with M&A-backed expansion strategy mirroring Labomar's.

Regional players

• Laboratorios Cinfa: Spanish pharmaceutical and consumer-health manufacturer with comparable portfolio of supplements, OTC and medical-device products. Comparable through Laboratorios Entema's geographic and product overlap, though primarily serving Iberian markets.

Broad incumbents

• Catalent: Global CDMO leader (now owned by Novo Holdings) with extensive consumer health and softgel capabilities. Broader and deeper-than-Labomar competitor in dosage-form CDMO, but addresses the same international pharmaceutical, nutraceutical, and consumer-health brand customers.
• Eurofins Scientific (CDMO / health ingredients): Global life-sciences testing and contract services group with growing CDMO and consumer-health product testing activities. Overlaps with Labomar through laboratory-based services, QA/QC, and packaging/serialization support for international brand customers.
• Syntegon (formerly Bosch Packaging Technology pharma unit): German-headquartered CDMO and equipment supplier for pharma and consumer health dosage forms, serving many of the same multinational brand customers. Adjacent overlapping offering at finished dosage and packaging CDMO level.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/labomar-srl
• Facebookfacebook.com/labomarspa

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries7 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LABOMAR